Comparing the current results to its competitors, Verve Therapeutics Inc reported Revenue increase in the 1 quarter 2025 by 479.03 % year on year. The sales growth was above Verve Therapeutics Inc 's competitors' average revenue growth of 7.95 %, achieved in the same quarter.
Verve Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and biopharmaceutical industries, focusing on cardiovascular disease (CVD). It faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research organizations. Competitors often possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing. Industry consolidation through mergers and acquisitions may concentrate resources among fewer competitors. Smaller or early-stage companies can also be significant competitors, particularly through collaborations with larger firms. Competition extends to securing qualified personnel, clinical trial sites, patient enrollment, and complementary technologies. Key factors influencing competitiveness in developing treatments for atherosclerotic cardiovascular disease (ASCVD) include efficacy, safety, convenience, price, generic competition, and reimbursement availability.
October 14, 2024
In recent weeks, Verve Therapeutics, Inc. a biotechnology company at the forefront of gene editing technology, has found itself embroiled in a class action securities lawsuit that aims to recover damages for its investors. The action has been brought forward by several law firms, including Levi and Korsinsky LLP and Rosen Law Firm, targeting those who purchased Verve’s securities between August 9, 2022, and April 1, 2024. This legal move raises significant questions about the company’s operational integrity and future prospects. The Nature of the AllegationsThe crux of the allegations against Verve Therapeutics appears to center around undisclosed negative information that may have misled investors durin...
April 2, 2024
Verve Therapeutics Announces Exciting Progress in PCSK9 Program with Heart-1 Clinical Trial ResultsVerve Therapeutics, a leading biopharmaceutical company pioneering gene editing technologies for cardiovascular diseases, recently shared compelling updates on its revolutionary PCSK9 program. The company reported remarkable results from the Heart-1 clinical trial, demonstrating drastic reductions in low-density lipoprotein cholesterol (LDL-C) levels using their investigational drug, VERVE-101.The PCSK9 protein plays a pivotal role in regulating cholesterol levels in the body. However, genetic mutations can lead to excessive PCSK9 activity, resulting in elevated LDL-C levels and an increased risk of cardiovascu...
Precigen Inc is a biotechnology company that focuses on the development and commercialization of innovative genetic therapies. Their business model revolves around leveraging their proprietary technologies and expertise in gene editing and synthetic biology to create transformative medical solutions. With a strong emphasis on research and development, Precigen aims to bring cutting-edge genetic therapies to market and address critical unmet medical needs.
Pepgen Inc is a biotechnology company that operates on a business model focused on developing and commercializing transformative therapies for genetic diseases. They leverage their expertise in synthetic biology and gene editing technologies to create novel peptide-based therapies that can address previously untreatable genetic conditions. Pepgen Inc aims to partner with healthcare organizations and pharmaceutical companies to bring their innovative treatments to market.
Molecular Templates Inc's business model involves the development and commercialization of innovative biologic drugs based on their proprietary engineered toxin bodies (ETBs) platform.
Marinus Pharmaceuticals Inc operates on a business model centered around developing and commercializing innovative therapeutics for rare neurological disorders.
Sources:
Verve Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Verve Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
